---
title: "Mono Pharmacare Ltd (MONOPHARMA) — Share Price, Financials & Analysis"
symbol: "MONOPHARMA"
company: "Mono Pharmacare Ltd"
canonical: "https://tapetide.com/stocks/MONOPHARMA"
isin: "INE0OIP01012"
nse_symbol: "MONOPHARMA"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 15.81
generated_at: "2026-09-13T19:03:41.293Z"
---

# Mono Pharmacare Ltd (MONOPHARMA)

Canonical page: https://tapetide.com/stocks/MONOPHARMA

## Company

- **NSE Symbol:** MONOPHARMA
- **ISIN:** INE0OIP01012
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2023-09-07
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** monopharmacareltd.com

## About

Incorporated in 1994, Mono Pharmacare Ltd is in the business of distribution of Pharmaceutical items[1]

## Latest Price

- **Price:** ₹8.95
- **Change:** 0 (0%)
- **Open:** ₹8.25
- **Day High:** ₹8.95
- **Day Low:** ₹8.25
- **Previous Close:** ₹8.95
- **Volume:** 0
- **As Of:** 2026-09-11T10:01:38+00:00

## Key Fundamentals

Observed at 2026-09-11T04:42:41.526566Z.

- **Market Cap:** ₹15.81 Cr
- **Classification:** SME
- **P/E (reported):** 44.8
- **EPS (reported):** ₹1.38
- **Book Value:** ₹17.86
- **Price to Book:** 0.5
- **Dividend Yield:** 0%
- **ROE:** 9.94%
- **ROCE:** 14.82%
- **Debt to Equity:** 1.75
- **Revenue (yearly):** ₹165.69 Cr
- **Net Income:** ₹0.32 Cr
- **EBITDA:** ₹3.99 Cr
- **52-Week High:** ₹25.5
- **52-Week Low:** ₹7.5
- **RSI (14):** 47.75

## Tapetide Score

- **Score:** 37 / 100
- **Score date:** 2026-08-26
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Falling
- **Percentile:** 9 (of 4468 scored stocks)
- **Confidence:** 86%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 19.07 | 9% |
| growth | 34.19 | 9% |
| momentum | 9.33 | 12% |
| ownership | 50 | 24% |
| quality | 30.67 | 22% |
| valuation | 50.93 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 0.50 times its book value

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 7.18% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 165 days.

## Growth Rates

| Metric | 1Y | 3Y |
| --- | --- | --- |
| cash flow growth | 50.97% | 89.12% |
| ebitda margin growth | -52.65% | -54.1% |
| net income growth | -89.68% | -28% |
| revenue growth | -2.13% | 71% |
| roce | 6.39% | 91.23% |
| roe | 13.73% | 8.53% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 35 | 67 | 56 | 87 | 81 | 66 | 99 |
| Expenses | 33 | 63 | 53 | 82 | 78 | 65 | 97 |
| Operating Profit | 2 | 4 | 2 | 5 | 3 | 2 | 2 |
| OPM % | 6 | 6 | 4.4 | 5 | 3.6 | 2.7 | 2.2 |
| Other Income | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 2 | 1 | 3 | 1 | 0 | 0 |
| Tax % | 39 | 20 | 33 | 27 | 37 | 83 | 29 |
| Net Profit | 1 | 2 | 1 | 2 | 1 | 0 | 0 |
| EPS in Rs | 0.52 | 1.06 | 0.33 | 1.3 | 0.46 | 0.01 | 0.19 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 6m | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 33 | 122 | 168 | 166 |
| Expenses | 31 | 116 | 161 | 162 |
| Operating Profit | 2 | 6 | 8 | 4 |
| OPM % | 7 | 5 | 4.5 | 2.4 |
| Other Income | 0 | 0 | 1 | 0 |
| Interest | 1 | 3 | 4 | 3 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 3 | 4 | 1 |
| Tax % | 29 | 24 | 30 | 40 |
| Net Profit | 1 | 2 | 3 | 0 |
| EPS in Rs | 0.76 | 1.38 | 1.75 | 0.2 |
| Dividend Payout % | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 12 | 18 | 18 | 18 |
| Reserves | 1 | 10 | 14 | 14 |
| Borrowings | 40 | 41 | 54 | 56 |
| Other Liabilities | 9 | 12 | 25 | 34 |
| Total Liabilities | 63 | 81 | 110 | 122 |
| Fixed Assets | 1 | 1 | 1 | 1 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 |
| Other Assets | 61 | 80 | 109 | 121 |
| Total Assets | 63 | 81 | 110 | 122 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | -40 | -9 | -4 | 2 |
| Cash from Investing Activity | -1 | 0 | 0 | 0 |
| Cash from Financing Activity | 41 | 8 | 5 | -2 |
| Net Cash Flow | 0 | 0 | 0 | 0 |
| Free Cash Flow | -40 | -9 | -5 | 2 |
| CFO/OP | -1765 | -127 | -38 | 64 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | 241 | 94 | 91 | 165 |
| Inventory Days | 408 | 139 | 133 | 99 |
| Days Payable | 87 | 32 | 45 | 68 |
| Cash Conversion Cycle | 563 | 202 | 179 | 196 |
| Working Capital Days | 299 | 131 | 120 | 126 |
| ROCE % | — | 10 | 11 | 5 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 38.13% | 37.21% | 36.69% | 35.27% | 35.6% | 34.48% | 33.28% |
| Others | 5.14% | 6.07% | 6.59% | 8.01% | 7.68% | 8.8% | 10% |
| No. of Shareholders | 972 | 528 | 418 | 463 | 478 | 514 | 529 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 7 / 3 / 9

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 8.86 | Buy |
| EMA (10) | 8.82 | Buy |
| SMA (20) | 8.54 | Buy |
| EMA (20) | 8.92 | Buy |
| SMA (50) | 9.84 | Sell |
| EMA (50) | 9.71 | Sell |
| SMA (100) | 11 | Sell |
| EMA (100) | 11.2 | Sell |
| SMA (200) | 14.75 | Sell |
| EMA (200) | 14.66 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 47.75 | Neutral |
| MACD (12,26,9) | -0.24 | Buy |
| Stochastic (14,3,3) | 86.96 | Sell |
| ADX (14) | 28.99 | Buy |
| Williams %R (14) | -4.35 | Sell |
| ATR (14) | 0.33 | High Volatility |
| ROC (12) | 5.92 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 66.48 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Sep - NSE levied ₹1,71,100 and ₹31,860 fines for delayed SEBI compliance filings. | [Updates 9 Sep - NSE levied ₹1,71,100 and ₹31,860 fines for delayed SEBI compliance filings.](https://nsearchives.nseindia.com/corporate/MONO_09092026174303_Board_Comments_on_reg_33_and_76.pdf) |
| 9 April 2026 - Mono Pharmacare Limited has informed about General Updatesregarding the deferment of extra-ordinary general meeting which is to held on 30th April 2026 | [General Updates 9 April 2026 - Mono Pharmacare Limited has informed about General Updatesregarding the deferment of extra-ordinary general meeting which is to held on 30th April 2026](https://nsearchives.nseindia.com/corporate/MONO_09042026170947_Intimation.pdf) |
| 8 June 2026 - Mono Pharmacare EGM on 30 June 2026 to appoint statutory auditor and independent director. | [Shareholders meeting 8 June 2026 - Mono Pharmacare EGM on 30 June 2026 to appoint statutory auditor and independent director.](https://nsearchives.nseindia.com/corporate/MONO_08062026155208_Notice.pdf) |
| 5 May 2026 - Mono Pharmacare Limited has informed regarding Resignation of Ms M/s. Kaliya & Associates, Chartered Accountant as Other of the company w.e.f. May 04, 2026. | [Resignation 5 May 2026 - Mono Pharmacare Limited has informed regarding Resignation of Ms M/s. Kaliya & Associates, Chartered Accountant as Other of the company w.e.f. May 04, 2026.](https://nsearchives.nseindia.com/corporate/MONO_05052026192957_Intimation_Letter.pdf) |
| 4 Sep - 4th AGM on 30 Sep 2026; shareholders to approve Rs. 80 crore related-party transactions and auditor reappointment. | [Shareholders meeting 4 Sep - 4th AGM on 30 Sep 2026; shareholders to approve Rs. 80 crore related-party transactions and auditor reappointment.](https://nsearchives.nseindia.com/corporate/MONO_04092026162055_AGM_Notice.pdf) |
| 30 May 2026 - RTA certificate under Regulation 74(5) for quarter ended March 31, 2026; no demat securities received. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 30 May 2026 - RTA certificate under Regulation 74(5) for quarter ended March 31, 2026; no demat securities received.](https://nsearchives.nseindia.com/corporate/MONO_30052026165730_74__5_.pdf) |
| 30 May 2026 - PIT compliance certificate confirms SDD maintained; 7 required events captured, with nil non-compliance for FY2026. | [Structural Digital Database 30 May 2026 - PIT compliance certificate confirms SDD maintained; 7 required events captured, with nil non-compliance for FY2026.](https://nsearchives.nseindia.com/corporate/MONO_30052026172639_SDD_Certificate.pdf) |
| 30 May 2026 - Mono Pharmacare Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q 4 FY 2025-26 | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 30 May 2026 - Mono Pharmacare Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q 4 FY 2025-26](https://nsearchives.nseindia.com/corporate/MONO_30052026165853_CG.pdf) |
| 30 March 2026 - Mono Pharmacare Limited has informed regarding Outcome of Board Meeting held on March 30, 2026. | [Outcome of Board Meeting 30 March 2026 - Mono Pharmacare Limited has informed regarding Outcome of Board Meeting held on March 30, 2026.](https://nsearchives.nseindia.com/corporate/MONO_30032026171620_Outcome_of_Board_Meeting.pdf) |
| 30 March 2026 - Mono Pharmacare Limited has informed regarding Change in Auditors of the company. | [Change in Auditors 30 March 2026 - Mono Pharmacare Limited has informed regarding Change in Auditors of the company.](https://nsearchives.nseindia.com/corporate/MONO_30032026193835_Intimation_For_Appointment_of_Auditor.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31385_MONOPHARMA_2025_2026_A_3697690_04092026163027.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28396_MONOPHARMA_2024_2025_A_1143955_04092025123834.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_26166_MONOPHARMA_2023_2024_07092024181332.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:03:41.293Z.